Market Overview

ICON and the International Consortium for Health Outcomes Measurement Unveil the World's First Global Patient Outcomes Benchmarking Platform


ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions
and services to the pharmaceutical, biotechnology and medical device
industries, and the International Consortium for Health Outcomes
Measurement (ICHOM), a non-profit organization with the mission of
driving value based health care, shared the findings of a global patient
outcomes benchmarking platform at this week's ICHOM's
annual conference
in Washington DC. The platform aims to catalyse
physician driven learning and improvement of the outcomes that matter
most to patients.

ICON and ICHOM first partnered to advance value-based healthcare through
the launch of a global
healthcare outcomes benchmarking pilot program
called GLOBE in March

The pioneering work of the GLOBE pilot program, through its
collaboration with a global network of participating sites who provided
de-identified data, has enabled the development of a global platform for
collecting, storing, aggregating, analysing and visualising health
outcomes data. In just under 18 months, ICON and ICHOM have processed in
excess of 200 data transfers, collected data from 70 health care
facilities and developed risk-adjustment algorithms based on over 75,000
procedures. This work was done in close collaboration with the provider
organizations who have full ownership of the data and the clinical
leaders and patients in the working groups who defined the datasets in
the first place.

The platform will provide decision support tools and insights to
participating health care organizations for optimising and improving
patient outcomes, using ICHOM developed Standard
. ICHOM Standard
provide a common language and approach to measuring outcomes at
the medical condition level – ICHOM currently has Standard Sets for 21
conditions that cover approximately 47% of the global disease burden.

Professor Ola Rolfson, Department of Orthopaedics, Institute of Clinical
Sciences Sahlgrenska Academy, University of Gothenburg, Sweden,
expressed: "The GLOBE pilot program brings good news. It is possible
to engage institutions globally in collecting ICHOM standard set data.
The results have helped understand variation and factors determining
outcomes. By continuous feedback and re-measuring, the program will keep
striving to improve outcomes by benchmarking as a network."

The platform has been developed using the widely accepted OMOP framework
to effectively benchmark outcomes across diverse health care
organizations. The Standard Set specific benchmarking visualizations
will be unveiled at ICHOM's annual conference on the 25th and 26th of
October 2017 and will be available via a provider portal in Q1 2018.

Professor Mats Lundstrom, Department of Clinical Sciences,
Ophthalmology, Faculty of Medicine, Lund University, Sweden stated: "The
use of a patient reported outcomes measure in cataract surgery is not
yet an established best practice. However, collecting and evaluating
important patient-reported data is of paramount importance in
understanding the patient's perspective of care. ICHOM's GLOBE pilot
program brings informed perspectives that cannot be overlooked in the
journey toward improving value for the patient."

Christina Rångemark Åkerman, President of ICHOM, commented: "The
GLOBE benchmarking pilot is an exciting example of outcomes in action.
For the first time, outcomes data from multiple hospitals around the
globe are collected and compared. The insights will provide great
opportunities to drive improvements in patient care via learning and
sharing of best practices between hospitals."

Dr. Steve Cutler, Chief Executive Officer, ICON plc, commented: ""Today's
launch marks a major milestone towards the realisation of ICHOM's and
ICON's shared vision of improving patient care.
The measurement
and sharing of outcomes will ultimately improve the clinical development
process by enabling better protocols that will lead to the development
of treatments that will be of most benefit to patients. We are proud to
have brought our clinical and technical expertise in health outcomes and
real-world data to help ICHOM create the first global healthcare
outcomes benchmarking platform."


The International Consortium for Health Outcomes Measurement (ICHOM) was
founded by Michael E. Porter, PhD, Bishop William Lawrence University
Professor at Harvard Business School, The Boston Consulting Group and
Professor Martin Ingvar, Karolinska Institutet with the mission to
unlock the potential of value-based health care by defining global
Standard Sets of outcome measures that really matter to patients for the
most relevant medical conditions and by driving adoption and reporting
of these measures worldwide. In January 18 2017 ICHOM and the
Organisation for Economic Cooperation and Development (OECD) signed a
Letter of Intent to collaborate on the collection, analysis and
publishing of patient reported outcomes for international comparison. To
date ICHOM have published Standard Sets covering 47 percent of the
global disease burden.

Further information is available at

About ICON plc

ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees.

Further information is available at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial